370 related articles for article (PubMed ID: 11600469)
21. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
Wright S; Sanders DS; Lobo AJ; Lennard L
Gut; 2004 Aug; 53(8):1123-8. PubMed ID: 15247179
[TBL] [Abstract][Full Text] [Related]
22. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Lowry PW; Franklin CL; Weaver AL; Szumlanski CL; Mays DC; Loftus EV; Tremaine WJ; Lipsky JJ; Weinshilboum RM; Sandborn WJ
Gut; 2001 Nov; 49(5):656-64. PubMed ID: 11600468
[TBL] [Abstract][Full Text] [Related]
23. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
Frick S; Müller D; Kullak-Ublick GA; Jetter A
Eur J Clin Pharmacol; 2019 Mar; 75(3):335-342. PubMed ID: 30610277
[TBL] [Abstract][Full Text] [Related]
24. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
de Boer NKH; Peyrin-Biroulet L; Jharap B; Sanderson JD; Meijer B; Atreya I; Barclay ML; Colombel JF; Lopez A; Beaugerie L; Marinaki AM; van Bodegraven AA; Neurath MF
J Crohns Colitis; 2018 Apr; 12(5):610-620. PubMed ID: 29293971
[TBL] [Abstract][Full Text] [Related]
25. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
Campbell S; Kingstone K; Ghosh S
Aliment Pharmacol Ther; 2002 Mar; 16(3):389-98. PubMed ID: 11876691
[TBL] [Abstract][Full Text] [Related]
26. Thiopurine metabolites and TPMT activity measurement in inflammatory bowel disease.
Louis E
Aliment Pharmacol Ther; 2011 Nov; 34(9):1138-9; author reply 1139-40. PubMed ID: 21981736
[No Abstract] [Full Text] [Related]
27. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
29. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
30. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
31. Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring.
el-Azhary RA; Farmer SA; Drage LA; Rogers RS; McEvoy MT; Davis MD; Bridges AG; Gibson LE
Arch Dermatol; 2009 Jun; 145(6):644-52. PubMed ID: 19528417
[TBL] [Abstract][Full Text] [Related]
32. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
Bradford K; Shih DQ
World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
[TBL] [Abstract][Full Text] [Related]
33. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
34. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
35. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Cuffari C; Hunt S; Bayless TM
Aliment Pharmacol Ther; 2000 Aug; 14(8):1009-14. PubMed ID: 10930894
[TBL] [Abstract][Full Text] [Related]
36. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab M; Herrlinger K; Schaeffeler E; Stange EF
Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
[No Abstract] [Full Text] [Related]
37. [Erythrocyte activity of thiopurine methyltransferase and treatment with thiopurines in inflammatory bowel disease].
Domènech Morral E; Gassull Duro MA
Med Clin (Barc); 2005 Sep; 125(8):293-4. PubMed ID: 16159553
[No Abstract] [Full Text] [Related]
38. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis.
Nguyen TM; Daubard M; Le Gall C; Larger M; Lachaux A; Boulieu R
Ther Drug Monit; 2010 Aug; 32(4):433-7. PubMed ID: 20479703
[TBL] [Abstract][Full Text] [Related]
39. [Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine].
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Med Clin (Barc); 2003 Jun; 121(1):1-5. PubMed ID: 12812701
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].
Jourdil N; Fonrose X; Boulieu R; Stanke-Labesque F;
Therapie; 2010; 65(3):177-86. PubMed ID: 20699068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
